Surgery Websites
Thoracic Oncology Lab »  Alumni »  Research Scientists »  Hio Chung Kang, Ph.D.
Hio Chung Kang, Ph.D.

Hio Chung Kang, Ph.D.

Assistant Research Biologist

Contact Information

UCSF Helen Diller Family Comprehensive Cancer Center
2340 Sutter St, Room N261
San Francisco, CA 94143-1724
(415) 502-0555
Open Popup
  • College of Science, Sookmyung Women's University, Korea, B.S., Biology, 1999
  • College of Medicine, Seoul National University, Korea, M.S., Tumor Biology, 2003
  • College of Medicine, Seoul National University, Korea, Ph.D., Tumor Biology, 2005
  • Staff Scientist, National Cancer Center Research Institute, Korea, 2005-2007
  • Postdoctoral fellow, Department of Pediatrics, University of California, San Francisco (UCSF), 2007-2008
  • Postdoctoral fellow, UCSF Cancer Center, 2008-2010
  • Associate Specialist, UCSF Cancer Center, 2011-2013
  • Thoracic Oncology Laboratory
  • Thoracic Oncology Program
  • UCSF Department of Surgery
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Cancer genetics and genomics
  • Carcinogensis in Ptch1 mutant mouse models
  • Discovery of candidate tumor suppressors and tumor promoters using genomic analysis
  • Identification of drug-resistant genes to the chemotherapies
  • Inherited cancer syndromes and germline mutations

Dr. Hio Chung Kang is an Assistant Research Biologist in Thoracic Oncology Laboratory at the UCSF Helen Diller Family Comprehensive Cancer Center which she joined in 2013.

Dr. Kang graduated from Sookmyung Women's University in Korea with a B.S. in Biology. She then received her M.S. and Ph.D. in Seoul National University, Korea in Tumor Biology. After she completed her doctoral work, Dr. Kang received an appointment as a staff scientist at the National Cancer Center Research Institute, Korea. Thereafter, in 2007, she came to UCSF, initially as a postdoctoral fellow, and now in the role of an Associate Specialist.

Dr. Kang has been an author on approximately forty peer-reviewed research papers related to her own research projects and in conjunction with collaborative researchers. In the past, she served as a principal investigator in the Genomic Core laboratory in National Cancer Center Research Institute.

At UCSF, Dr. Kang has played a pivotal role in coordinating genomic analysis - gene expression analysis, genome-wide genotyping, next-generation sequencing, through her management of a mouse tissue bank constructed from a number of  mouse tumor models.

Dr. Kang's research interest focuses on the understanding of cancer as a genetic disease, the identification of tumor susceptibility genes and the genomic signature of cancer cells, all with the goal of discovering new therapeutic targets and drug resistance genes. Dr. Kang has explored genetic alterations in various inherited cancer syndromes as well as mutations in sporadic solid tumors, genome-wide expression profiling of acquired drug-resistant cancer cells, polymorphic variants associated with cancer risk, and chemically induced carcinogenesis in genetically engineered mouse models.

Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, Lee SY, Kim KH, Shin Y, Noh DY, Yang DH, Choe KJ, Lee BH, King SB, Park JG. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat. 2002; 20: 235

Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG, Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res. 2004; 10: 272-84. selected as Feature article of the issue

Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA, Ku JL, Chang HJ, Yoo BC, Kim HK, Yoon SN, Park JG. Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs. Cancer Lett 2007; 247(1):40-74.

Kang HC, Quigley D, Kim IJ, Wakabayashi Y, Ferguson-Smith MA, D'Alessandro M, E Lane B, Akhurst RJ, Goudie DR, and Balmain A. Multiple Self-Healing Squamous Epithelioma (MSSE): rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology. J Invest Dermatol. 2013 Jan 28

Kang HC, Wakabayashi Y, Jen KY, Mao JH, Zoumpourlis V, Del Rosario R, and Balmain A. Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14PtchFVB mice. J Invest Dermatol. J Invest Dermatol. 2013 May;133(5):1311-20


Site Directory